REGENXBIO (RGNX) to Announce Quarterly Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $97.6290 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.36). The company had revenue of $6.39 million during the quarter, compared to analysts’ expectations of $25.84 million. REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. On average, analysts expect REGENXBIO to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

REGENXBIO Trading Up 2.8%

REGENXBIO stock opened at $9.96 on Tuesday. The stock has a market cap of $514.93 million, a PE ratio of -1.78 and a beta of 0.94. The stock has a 50-day moving average price of $9.70 and a 200 day moving average price of $9.49. REGENXBIO has a 52 week low of $5.45 and a 52 week high of $16.19.

Insider Buying and Selling

In other REGENXBIO news, insider Steve Pakola sold 2,161 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total transaction of $29,476.04. Following the completion of the sale, the insider directly owned 213,009 shares in the company, valued at $2,905,442.76. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 73,803 shares of company stock worth $886,937 in the last ninety days. Corporate insiders own 14.22% of the company’s stock.

Institutional Trading of REGENXBIO

Institutional investors have recently modified their holdings of the company. Aquatic Capital Management LLC acquired a new position in REGENXBIO during the third quarter valued at approximately $37,000. Captrust Financial Advisors acquired a new stake in shares of REGENXBIO in the second quarter worth $85,000. Balyasny Asset Management L.P. acquired a new stake in shares of REGENXBIO in the fourth quarter worth $150,000. Prudential Financial Inc. purchased a new position in shares of REGENXBIO in the 2nd quarter valued at $87,000. Finally, CANADA LIFE ASSURANCE Co boosted its position in REGENXBIO by 271.8% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 10,839 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 7,924 shares during the period. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on RGNX shares. Robert W. Baird raised their price target on shares of REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Zacks Research lowered REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Bank of America dropped their price objective on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, May 15th. HC Wainwright reiterated a “buy” rating and set a $26.00 price objective on shares of REGENXBIO in a report on Wednesday, July 1st. Finally, Barclays decreased their target price on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, May 15th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $23.82.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.